Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 312 across all filing types
Latest filing 2023-11-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - VBS 7 pages 32.2KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities under an employee incentive scheme by Vectus Biosystems Limited. It details the number and type of securities issued, dates, and compliance with ASX listing rules. The content focuses on the issuance of new securities, specifically unquoted options, and includes references to ASX rules and employee incentive plans. There is no financial performance data, management discussion, or audit information. The document is an announcement of a capital change event related to securities issuance, not a full report or financial statement. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a formal notification of securities issuance.
2023-11-19 English
Quarterly Activities/Appendix 4C Cash Flow Report 7 pages 440.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which mandates quarterly reporting. It includes detailed financial data such as cash flow statements, operating activities, investing activities, and financing activities for the quarter ended 30 September 2023. The document also contains commentary on business activities during the quarter, patent grants, and corporate finance updates. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2023-10-30 English
Notice of Annual General Meeting & Proxy Form 12 pages 671.6KB
AGM Information Classification · 100% confidence The document is titled '2023 Annual General Meeting' and contains detailed information about the upcoming AGM of Vectus Biosystems Limited, including the date, time, virtual meeting details, and instructions for shareholders. It includes the Notice of the AGM, the business to be conducted (such as receiving the Annual Report, re-election of a director, adoption of the Remuneration Report, share issue approval, and employee incentive plan approval). It also contains voting exclusion statements, proxy instructions, and explanatory notes related to the AGM agenda items. The document does not contain the actual Annual Report or financial statements but refers to them and states they will be laid before the meeting. This is consistent with an AGM Information document, which provides materials and notices related to the Annual General Meeting rather than the full Annual Report or financial statements themselves. The document length (15,000 characters) and content confirm it is a detailed AGM notice and explanatory notes, not the report itself or a voting results announcement. Therefore, the correct classification is AGM Information (AGM-R).
2023-10-16 English
Date of 2023 Annual General Meeting 1 page 119.3KB
AGM Information Classification · 95% confidence The document is a short announcement dated 4 October 2023 from Vectus Biosystems Limited regarding the scheduling of the 2023 Annual General Meeting (AGM). It provides details about the date, time, virtual attendance, and nomination deadline for director elections. There is no detailed financial data, report content, or presentation materials included. The document is clearly an announcement about the AGM event rather than the AGM materials themselves. The length is only 1074 characters, which is short and consistent with an announcement rather than a full report or presentation. Therefore, this fits the category of AGM Information (AGM-R).
2023-10-03 English
Change of Share Registrar to Computershare 1 page 1
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 22 September 2023 from Vectus Biosystems Limited regarding a change in the company's share registry service provider. It provides contact details for the new share registry and instructions for shareholders to register online. There is no financial data, no discussion of financial results, no mention of a report being attached or published, and no regulatory certifications. The content is purely informational about a change in shareholder services. According to the classification rules, this type of announcement does not fit into financial reports or management information categories. It is a general regulatory announcement about shareholder services, best classified under Regulatory Filings (RNS). The document length is under 5,000 characters and it is not announcing a report publication, so it is not RPA. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-09-21 English
Preliminary Final Report - Appendix 4E 1 page 161.2
Earnings Release Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report for the financial year ended 30 June 2023' and includes financial results for the year ended 30 June 2023. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are announcements of full year financial results but are not the full annual report (10-K equivalent). The document contains summary financial data, results for announcement to the market, and notes on dividends and audit status. It is a concise report primarily for market announcement purposes rather than a full annual report. Given the length (2558 characters) and content, it fits the category of an Earnings Release (ER) or a Regulatory Filing (RNS). However, Appendix 4E is specifically a preliminary final report announcement, which aligns with an Earnings Release (ER) as it announces full year results with key highlights. Therefore, the best classification is Earnings Release (ER).
2023-08-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.